AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05345041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Keep it Movin'
Description: Individual participants in churches randomized to the intervention arm will participate in the Keep it Movin' multi-component PA education program, as well as be encouraged by their church and study interventionist to participate in the church-wide walking program. Individuals enrolled in Keep It Movin' will attend weekly 90-minute sessions for 24 weeks. All sessions will include the structured physical activity component from the LIFE study intervention, with the following components, which were added to address needs of the target community: functional education, social support and problem-solving. To increase the functional gains seen in the LIFE pilot study and add content addressing self-management and PA with multiple chronic conditions (MCCs), the number of sessions in the proposed trial has been increased from 16 to 24 weeks.
Study NCT05345041 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Go 4 Life Self Guided Education
Description: Individual participants in churches randomized to the comparator arm will receive the church-wide walking program and the Go4Life Your Everyday Guide to Exercise and Physical Activity which was developed by the National Institutes of Health National Institute on Aging to promote physical activity in older adults. This includes an evidence-based exercise guide and motivational tips to help older adults start and sustain an exercise program. The Go4Life guide will add individual level education and encouragement to the interpersonal and community levels of intervention provided by the church-wide walking program.
Study NCT06470841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHG Combined With Venetoclax and Azacytidine
Description: Patients were treated by CHG Combined With Venetoclax and Azacytidine:~Venetoclax 100mg po qd d1, 200mg po qd d2, 400mg po qd d3-14; Azacytidine 75 mg/m2 subcutaneous injection qd d1-7; Homoharringtonine 1mg/m2 iv qd d1-14; Cytarabine 10mg/m2 subcutaneous injection q12h d1-14; G 250ug/m2 subcutaneous injection qd d0-14.
Study NCT05557487 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Low dose computed tomography
Description: 1. Participants belonging to modified Lung RADS category 1 and 2 at baseline screening will undergo the LDCT next year after the discussion with the physicians in charge.~2. Participants with nodules belonging to modified Lung RADS category 3 and 4, growing nodules, or new nodules found on follow-up LDCT scans will undergo repeat CT every 3 to 6 months or be referred for diagnostic workup depending on the size and characteristics of the nodules as the regular clinical practice.~3. Volume doubling time (VDT) will be performed in the special groups with Lung RADS category 3 or 4, but the nodules with solid components ≧ 6mm and \< 9mm. A repeat LDCT scan will be performed around 3 months after the baseline screening.~4. Check total bilirubin, urinary heavy metals,CRP, serum tumor marker, including CEA, alpha-fetal protein, etc.~5. Check pulmonary function test.
Study NCT04876027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 RAs
Description: GLP-1 receptor agonist is a glucagon-like peptide 1 analog, which is related to improving blood sugar control, weight loss and appetite suppression, and reducing cardiovascular risk.
Study NCT04876027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: calorie restricted diet
Description: Calorie restricted diet can improve insulin sensitivity, liver fat in patients with visceral obesity, and metabolism and hormone levels in obese women with PCOS.
Study NCT04876027 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: calorie restricted diet
Description: Calorie restricted diet can improve insulin sensitivity, liver fat in patients with visceral obesity, and metabolism and hormone levels in obese women with PCOS.
Study NCT05378867 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRS003
Description: * TRS003, 5 mg/kg IV every 14 days with mFOLFOX6 for 1 cycle followed by switch to:~* Bevacizumab®, 5 mg/kg IV every 14 days with mFOLFOX6 for 1 cycle followed by switch to:~* TRS003, 5 mg/kg IV every 14 days with mFOLFOX6 until end of treatment due to PD, intolerability or other cause for stopping treatment. Intensive PK sampling will be performed after 7 cycles of this TRS003 switch period
Study NCT05378867 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: China-approved Bevacizumab
Description: • Bevacizumab®, 5 mg/kg IV every 14 days with mFOLFOX6 for 1 cycle
Study NCT05378867 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: China-approved Bevacizumab
Description: • Bevacizumab®, 5 mg/kg IV every 14 days with mFOLFOX6 for 1 cycle
Study NCT05378867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6
Description: The mFOLFOX6 regimen is:~* Oxaliplatin, 85 mg/m2 administered IV over 2 hours~* LCV, 400 mg/m2 administered over 2 hours concurrent with oxaliplatin~* 5-FU, 400 mg/m2 given as a slow IV push (bolus) over 5 minutes administered immediately after LCV~* 5-FU, 2400 mg/m2 administered IV over 46 hours by infusion pump beginning immediately after FU IV bolus.
Study NCT05378867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: The mFOLFOX6 regimen is:~* Oxaliplatin, 85 mg/m2 administered IV over 2 hours~* LCV, 400 mg/m2 administered over 2 hours concurrent with oxaliplatin~* 5-FU, 400 mg/m2 given as a slow IV push (bolus) over 5 minutes administered immediately after LCV~* 5-FU, 2400 mg/m2 administered IV over 46 hours by infusion pump beginning immediately after FU IV bolus.
Study NCT05173467 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted Invasion-controlled Surgery
Description: The concept of invasion-controlled surgery (ICS) for spinal metastasis has been put forward against the spinal instability and neurological dysfunction of frail patients that might not allowed for radical traditional open surgery including improvements of multidisciplinary dynamic assessments, endovascular detachable balloon embolization, minimal-invasion by using expandable working tubes, percutaneous pedicle screws, and some accurate therapy. ICS could provide immediate stability, deformity correction, and recovery of neurological function.
Study NCT05173467 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Traditional-open Surgery
Description: This traditionally requires a midline incision, bilateral muscle strip, and multilevel laminectomy to provide adequate access and safe removal of the tumor.
Study NCT06567457 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCB-2023B vaccine, a monovalent Omicron XBB.1.5 recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
Description: intramuscular injection
Study NCT06567457 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SCB-2019 vaccine, a monovalent wu-hu1 SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
Description: intramuscular injection
Study NCT05937750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imlifidase administered in the 20-HMedIdeS-19 (PAES) study
Description: Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
Study NCT05937750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best available treatment administered in the 20-HMedIdeS-19 (PAES) study
Description: Normal transplantation routine Transplantation and pre- and post-transplantation therapies in accordance with the clinic's normal transplantation routine.
Study NCT06105008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Disitamab Vedotin
Description: 2.0 mg/kg intravenous (lV) infusion every 2 weeks
Study NCT06105008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin
Description: 2.0 mg/kg intravenous (lV) infusion every 2 weeks
Study NCT06105008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 3.0 mg/kg intravenous (lV) infusion every 2 weeks
Study NCT05828498 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: THE Mediterranean diet
Description: The Mediterranean diet was applied to the patients with bacterial vaginitis selected randomly. diet content and application techniques were explained to the patient.
Study NCT01333592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAD-1229
Study NCT06147193 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: with baseline intervention and power training interventions
Description: Group A (with power training ) was treated with~* squats jump,~* change of direction speed,~* countermovement jump,~* bench press,~* Romanian deadlift~* barbell squats,~* resistance band sprints,~* stair sprints~* weighted sled pulls
Study NCT06147193 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: baseline interventions and without power training interventions
Description: Group B (without power training) was treated with~* squats jump~* change of direction speed~* countermovement jump~* barbell squats~* resistance band sprints~* stair sprints~* Weighted sled pulls.
Study NCT05634681 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Plan of the day
Description: Several treatment plans are prepared and the appropriate plan is used at each treatment session.
Study NCT06463990 — intervention group
Intervention type: OTHER
Intervention: TyG index
Description: association between TyG index and triglyceride to high-density lipoprotein cholesterol ratio with fetal macrosomia
Study NCT06151873 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Adapted sport
Description: control group sample, healthy subjects without musculoskeletal, neurological or vestibular alterations can participate.
Study NCT06151873 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Adapted sport
Description: Subjects with cerebral palsy/acquired brain damage belonging to the Spanish National Soccer Team with cerebral palsy and acquired brain damage may participate as an experimental group.
Study NCT05634681 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard plan
Description: One treatment plan
Study NCT06540820 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dexa or Biompedance analysis with clinical and biochemical evaluations
Description: All patients will undergo body composition study with DXA or Bioimpedance analysis which are the gold standard to determine % of fat mass and fat free mass, basal biochemical examinations and oral glucose tolerance test (OGTT), and clinical evaluation with waist circumference measurement. Moreover, all patients will undergo REMS ultrasound, TBS and BSI evaluation at DXA scan and hand grip test. In addition, all patients will undergo to clinical evaluation with specific nutritional, physical activity and sleep quality questionnaire assessments and an additional volume of blood.
Study NCT06319573 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling Supported by Univfy® Report
Description: The intervention consists of patients being counseled with the Univfy® PreIVF report during their second consultation. They will also be asked to fill in the same anonymous online questionnaire.
Study NCT06319573 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Counseling
Description: Patients in this group will be counseled as per standard care during their second consultation. They will be asked to complete an anonymous online validated questionnaire (see below) to assess their responses to the anonymous online questionnaire after consultation.
Study NCT05596552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyperbaric bupivacaine and dexmedetomidine
Description: In a 3 ml syringe, 5 µg dexmedetomidine was added to the 2 ml of 10 mg hyperbaric bupivacaine, to have a total volume of 2.5 ml for intrathecal spinal injection over 3 minute without barbotage
Study NCT05596552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-Fentanyl group
Description: In a 3 ml syringe, 25 μg fentanyl was added to the 2 ml of 10 mg hyperbaric bupivacaine, to have a total volume of 2.5 ml for intrathecal spinal injection over 3 minute without barbotage
Study NCT05326997 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation group
Description: Participants will have their face sanitized with micellar water (a cosmetic product for cleaning and makeup remover), followed by cleaning with soap. Then, the eyes will be protected with gauze, proper glasses and a black towel on top, a headset with relaxation music will also be placed and then the face will receive the treatment with yellow light. After the session the face will receive sunscreen. A placebo cosmetic will be given to the participant to be applied twice a day and daily sunscreen.
Study NCT05326997 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group control (Tranexamic acid)
Description: Participants will have their face sanitized with micellar water. Then, the eyes will be protected with gauze, proper glasses and a black towel on top, a headset with relaxation music will also be placed and then the face will receive the treatment with yellow light sham. The person responsible for applying the PBM will simulate the irradiations by positioning the device in the same places described for the PBM group, however, the equipment will be kept off. After the session the face will receive sunscreen. Will be delivered to patients, liposomal tranexamic acid with use 2 x a day home care and daily sunscreen.
Study NCT05903924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tradipitant
Description: Oral Capsule
Study NCT05903924 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Capsule
Study NCT03544606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isosorbide mononitrate
Description: 40 mg tablet of intra-vaginal IMN (Effox; MINAPHARMA, Cairo, Egypt) will be placed into the posterior fornix of the vagina, through a digital vaginal examination, every 4 h for a maximum of four doses.
Study NCT03544606 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: In placebo group (group 2) 40 mg intra-vaginal pyridoxine placebos every 4 h for a maximum of four doses will be given
Study NCT05149807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701 injection
Description: SHR-1701 injection Tegafur Gimeracil Oteracil Potassium Oxaliplatin
Study NCT05149807 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Tegafur Gimeracil Oteracil Potassium Oxaliplatin
Study NCT05070169 — intervention group
Intervention type: PROCEDURE
Intervention: Early Surgical Fixation vs. Delayed Surgical Fixation
Description: Evaluation of the reduction of the peri-operative blood loss in patients undergoing early surgical fixation (within 24 hours) of an intertrochanteric fracture under DOAC therapy compared to a retrospectively enrolled group of patients who underwent delayed surgical fixation (≥48 hours) of an intertrochanteric fracture under DOAC therapy.
Study NCT06564467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMT202
Description: subcutaneous injection
Study NCT06564467 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placrbo
Description: subcutaneous injection
Study NCT06251154 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens 1
Description: Daily disposable silicone hydrogel contact lens (diameter=14.0mm) for 15 minutes
Study NCT06251154 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens 2
Description: Daily disposable silicone hydrogel contact lens (diameter=14.1mm) for 15 minutes
Study NCT06433765 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05494723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YB-1113
Description: Human umbilical cord tissue-derived mesenchymal stem cells (hUC-MSC)
Study NCT06568666 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar spinal manipulation
Description: Lumbar spinal manipulation was performed in the lateral recumbent position and HVLA thrust was applied to the segment where dysfunction was detected. The spinal process was determined as the contact point and the direction of HVLA thrust was from posterior to anterior.
Study NCT06568666 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sacroiliac joint manipulation
Description: The participant lies on his/her side on the healthy side; the lower knee is in extension while the upper knee is flexed and placed in the popliteal fossa of the lower knee. The participant's hands are left free on the ribs at the lower level. The practitioner crosses the movement barrier with the stabilizing hand, allowing the tissues to relax. The practitioner performs HVLA thrust of the iliac bone into posterior or anterior rotation (in the opposite direction of dysfunction) with the stabilizing hand
Study NCT06317337 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: focused ultrasound cavitation augmented with aerobic exercises
Description: Ultrasound cavitation single session per week along with the Aerobic exercises. Aerobic Exercise was Treadmill walk for 30 min with moderate intensity
Study NCT06317337 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: focused ultrasound cavitation augmented with aerobic exercises
Description: Ultrasound cavitation single session per week along with the Aerobic exercises. Aerobic Exercise was Treadmill walk for 30 min with moderate intensity
Study NCT05489523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis 61 MG
Description: Tafamidis 61 mg by mouth daily for 12 months
Study NCT04593589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Submandibular Gland Stem Cell Transplantation
Description: Autologous transplantation of salivary stem cells (salisphere derived cells) cultured in vitro as obtained from submandibular glands after postoperative radiotherapy
Study NCT04991116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TILD sub-cutaneous (SC) injection
Description: 1 mL injection of study medication
Study NCT06389968 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light stimulation
Description: see arm description
Study NCT06389968 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham light stimulation
Description: see arm description
Study NCT06569680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Mosunetuzumab will be administered via subcutaneous (SC) injection using a step-up dosing model. Participants will receive Mosunetuzumab on days 1, 8, and 15 of Cycle 1, and on day 1 of Cycles 2 through 8 as follows:~* Cycle 1 Day 1: 5mg~* Cycle 1 Day 8: 45mg~* Cycle 1 Day 15: 45mg~* Cycles 2 through 8, Day 1: 45mg
Study NCT05510856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Duloxetine 30mg / day for 12 cycles (up to 6 months)
Study NCT05510856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 300 mg / day for 12 cycles (up to 6 months)
Study NCT05510856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide 50 mg / day for 12 cycles (up to 6 months)
Study NCT06243016 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High-Intensity Interval Training (HIIT) Breaks to Sitting
Description: HIIT Breaks: a 3.5-hour sitting will be interrupted every 30 min with 6-min HIIT Breaks. During sitting participants will engage in standardized sedentary activities. Each 6-min HIIT break comprises a one-minute warm-up, followed by a 2-minute high-intensity interval, one minute rest (sitting on a cycle ergometer) followed by another 2 minutes at high intensity.
Study NCT06243016 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Light-Intensity Interval Training (LIIT) Breaks to Sitting
Description: LIIT Breaks: a 3.5-hour sitting will be interrupted every 30 min with 6-min LIIT Breaks. Each 6-min LIIT break comprises a one-minute warm-up, followed by a 2-minute light-intensity interval, one minute rest (sitting on a cycle ergometer) followed by another 2-minute light-intensity interval.
Study NCT05465187 — intervention group
Intervention type: OTHER
Intervention: Non applicable
Description: Non applicable
Study NCT05340426 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UKidney
Description: The intended clinical product is a kidney derived from a domestic pig that contains an intentional genomic alteration (IGA) to protect it after transplantation from the human immune response via inactivation of endogenous porcine genes responsible for expression of pig epitopes and inclusion of human transgenes to inhibit host immunogenic response.
Study NCT04832204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib and Camrelizumab for Injection
Description: Apatinib 250mg, Qd, oral administration,SHR-1210 200mg, q3w one week later, intravenous administration, continuous administration until the disease progresses or an intolerable adverse reaction occurs.
Study NCT06533202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational Programme
Description: The objective of this type of programme is to equip individuals with the knowledge and skills required to navigate the challenges and capitalise on the opportunities presented by retirement. In particular, the programme strives to enhance the quality of life and attitudes towards retirement, elevate levels of life satisfaction, psychological flexibility, perceived social support and general health, self-efficacy and self-regulation, and mitigate stereotypes associated with ageing.